Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

This article was originally published in PharmAsia News

Executive Summary

Medivation has been here before and apparently likes the terrain. In a deal similar to last year's partnership with Pfizer on Dimebon, the company announced on Oct. 27 that it will receive a $110 million upfront payment to collaborate with Astellas on the development and commercialization of its Phase III prostate cancer candidate MDV3100

You may also be interested in...



Japan Earnings Roundup: Astellas' Oncology Gains, Eisai Hit Hard, KHK Domestic Strength

Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia

Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia

Related Content

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel